VT begets VT--and other bad stuff--in patients treated with CRT-D.

S. Jamal,R. Berger

DOI: https://doi.org/10.1016/j.hrthm.2013.04.024

IF: 6.779

2013-07-01

Heart Rhythm

Abstract:

What problem does this paper attempt to address?

Molecular Mechanisms and Clinical Applications of Mir-22 in Regulating Malignant Progression in Human Cancer (Review)

Jingyu Wang,Yuan Li,Meiman Ding,Honghe Zhang,Xiaoming Xu,Jinlong Tang

DOI: https://doi.org/10.3892/ijo.2016.3811

2016-01-01

International Journal of Oncology

Abstract:miRNAs (microRNAs) have been validated to play fateful roles in the occurrence and development of cancers by post-transcriptionally targeting 3′-untranslated regions of the downstream gene mRNAs to repress mRNA expression. Mounting investigations forcefully document that not only does miR-22 biologically impinge on the processes of senescence, energy supply, angiogenesis, EMT (epithelial-mesenchymal transition), proliferation, migration, invasion, metastasis and apoptosis, but also it genetically or epigenetically exerts dual (inhibitory/promoting cancer) effects in various cancers via CNAs (copy number alterations), SNPs (single nucleotide polymorphisms), methylation, acetylation and even more momentously hydroxymethylation. Additionally, miR-22 expression may fluctuate with cancer progression in the body fluids of cancer patients and miR-22 could amplify its inhibitory or promoting effects through partaking in positive or negative feedback loops and interplaying with many other related miRNAs in the cascade of events, making it possible for miR-22 to be a promising and complementary or even independent cancer biomarker in some cancers and engendering profound influences on the early diagnosis, therapeutics, supervising curative effects and prognosis.
Mir-22 Has a Potent Anti-Tumour Role with Therapeutic Potential in Acute Myeloid Leukaemia

Xi Jiang,Chao Hu,Stephen Arnovitz,Jason Bugno,Miao Yu,Zhixiang Zuo,Ping Chen,Hao Huang,Bryan Ulrich,Sandeep Gurbuxani,Hengyou Weng,Jennifer Strong,Yungui Wang,Yuanyuan Li,Justin Salat,Shenglai Li,Abdel G. Elkahloun,Yang,Mary Beth Neilly,Richard A. Larson,Michelle M. Le Beau,Tobias Herold,Stefan K. Bohlander,Paul P. Liu,Jiwang Zhang,Zejuan Li,Chuan He,Jie Jin,Seungpyo Hong,Jianjun Chen

DOI: https://doi.org/10.1038/ncomms11452

IF: 16.6

2016-01-01

Nature Communications

Abstract:MicroRNAs are subject to precise regulation and have key roles in tumorigenesis. In contrast to the oncogenic role of miR-22 reported in myelodysplastic syndrome (MDS) and breast cancer, here we show that miR-22 is an essential anti-tumour gatekeeper in de novo acute myeloid leukaemia (AML) where it is significantly downregulated. Forced expression of miR-22 significantly suppresses leukaemic cell viability and growth in vitro , and substantially inhibits leukaemia development and maintenance in vivo . Mechanistically, miR-22 targets multiple oncogenes, including CRTC1 , FLT3 and MYCBP , and thus represses the CREB and MYC pathways. The downregulation of miR-22 in AML is caused by TET1/GFI1/EZH2/SIN3A-mediated epigenetic repression and/or DNA copy-number loss. Furthermore, nanoparticles carrying miR-22 oligos significantly inhibit leukaemia progression in vivo . Together, our study uncovers a TET1/GFI1/EZH2/SIN3A/miR-22/CREB-MYC signalling circuit and thereby provides insights into epigenetic/genetic mechanisms underlying the pathogenesis of AML, and also highlights the clinical potential of miR-22-based AML therapy.
Depletion of Ars2 inhibits cell proliferation and leukemogenesis in acute myeloid leukemia by modulating the miR-6734-3p/p27 axis

Xiaoye Hu,Shuangnian Xu,Yibiao Chen,Ziyi Gao,Yunong Li,Jinjiao Hu,Xiuning Huang,Yanhao Zhang,Xiuxing Jiang,Lirong Li,Chong Yang,Jieping Chen,Ning Gao

DOI: https://doi.org/10.1038/s41375-018-0301-z

2018-12-05

Leukemia

Abstract:Ars2 is a component of the nuclear cap-binding complex (CBC) that contributes to microRNA biogenesis and is required for cellular proliferation. Little is known regarding the functional role of Ars2 in cell proliferation and leukemogenesis of acute myeloid leukemia. Here, we show that the elevated expression of Ars2 was observed in acute myeloid leukemia (AML) cell lines and bone marrow samples from AML patients and was correlated with poorer overall survival. Overexpression of Ars2 promoted cell proliferation and colony formation in AML cells, whereas depletion of Ars2 inhibited cell proliferation and colony formation. Mechanistic studies reveal that depletion of Ars2 suppressed the interaction of Ars2 with CBC and led to alterations in miRNA processing. Furthermore, Ars2 depletion reduced the levels of miR-6734-3p, resulting in upregulation of p27 and culminating in cell cycle arrest at the G1 phase. In vivo studies indicate that depletion of Ars2 significantly reduced leukemic cell burden and prolonged the survival time of the leukemia-bearing mice. These findings indicate that Ars2 may not only play a crucial role in the regulation of cell proliferation and leukemogenesis, but could also be identified as a critical therapeutic target for treatment of AML.

oncology,hematology
MicroRNA-191, Regulated by HIF-2α, is Involved in EMT and Acquisition of a Stem Cell-Like Phenotype in Arsenite-Transformed Human Liver Epithelial Cells.

Chao Chen,Qianlei Yang,Dapeng Wang,Fei Luo,Xinlu Liu,Junchao Xue,Ping Yang,Hui Xu,Jiachun Lu,Aihua Zhang,Qizhan Liu

DOI: https://doi.org/10.1016/j.tiv.2017.12.016

IF: 3.685

2018-01-01

Toxicology in Vitro

Abstract:Inorganic arsenic is widely distributed in the environment, and epidemiologic data show a strong association between arsenic exposure and risk of liver cancer. An understanding of the mechanisms underlying development of liver cancer and metastasis would be useful in reducing the incidence and mortality of liver cancer. MicroRNAs (miRs) act as regulators in liver cancer. Here, we show that acute or chronic exposure of human liver epithelial L-02 cells to arsenite increased expression of miR-191. There were decreased levels of BASP-1 and E-cadherin and increased levels of WT-1 and N-cadherin, indicating that arsenite induced epithelial-mesenchymal transition (EMT). Moreover, arsenite increased EpCAM and CD90 mRNA levels, showing the acquisition of stem cell-like properties by these cells. Suppression of miR-191 resulted in repression of EMT and reduced expression of stem-cell markers. Further, a miR-191 inhibitor blocked spheroid formation and production of side population cells. Luciferase reporter assays indicated that miR-191 was a target of HIF-2α, and inhibition of miR-191 decreased the neoplastic and metastatic properties of arsenite-transformed L-02 cells. Thus, in arsenite-transformed liver epithelial cells, transcriptional activation of the miR-191 promoter by HIF-2α is involved in EMT and in the acquisition of a stem cell-like phenotype.
Microrna Expression Alteration after Arsenic Trioxide Treatment in HepG‐2 Cells

Xian-Zhi Meng,Tong-Sen Zheng,Xi Chen,Jia-Bei Wang,Wei-Hui Zhang,Shang-Ha Pan,Hong-Chi Jiang,Lian-Xin Liu

DOI: https://doi.org/10.1111/j.1440-1746.2010.06317.x

2010-01-01

Journal of Gastroenterology and Hepatology

Abstract:BACKGROUND AND AIM:More and more microRNA (miRNA) are found to be involved in tumor genesis and progress. Arsenic trioxide has been an effective chemotherapeutic drug in cancer therapy for many years. In this study, we aimed to find the miRNA involved in the mechanisms of arsenic trioxide treatment in cancer therapy.METHODS:We detected the expression profile of miRNA by miRNA microarray and quantitative real-time polymerase chain reaction. Cell viability assay, flow cytometry analysis, prediction of miRNA targets, Western blot analysis and luciferase reporter assay were carried out to determine the role of one selected miRNA, namely mir-29a, in affecting the biological behaviors of HepG-2 cells.RESULTS:Among the 677 human miRNA in the microarray, five miRNA were upregulated and four were downregulated in HepG-2 cells treated with arsenic trioxide compared to their controls. If only changes above two folds were considered, four miRNA were identified, namely miR-24, miR-29a, miR-30a and miR-210, which were all upregulated. Among them, miR-29a showed a positive therapeutic effect in liver cancer cells by inhibiting cell growth and inducing cell apoptosis, and PPM1D was confirmed to be the target gene of miR-29a. Furthermore, a synergy effect was detected between miR-29a and arsenic trioxide.CONCLUSIONS:Arsenic trioxide altered miRNA expression profile in HepG-2 cells. Among the altered miRNA, miR-29a seemed to take a role in the mechanism of arsenic trioxide in liver cancer therapy. The synergy effect between miR-29a and arsenic trioxide may offer this drug a new chance in cancer therapy by decreasing its dose and toxic side-effects.
Role and Mechanism of Mir-222 in Arsenic-Transformed Cells for Inducing Tumor Growth

Min Wang,Xin Ge,Jitai Zheng,Dongmei Li,Xue Liu,Lin Wang,Chengfei Jiang,Zhumei Shi,Lianju Qin,Jiayin Liu,Hushan Yang,Ling-Zhi Liu,Jun He,Linlin Zhen,Bing-Hua Jiang

DOI: https://doi.org/10.18632/oncotarget.7525

2016-01-01

Oncotarget

Abstract:High levels of arsenic in drinking water, soil, and air are associated with the higher incidences of several kinds of cancers worldwide, but the mechanism is yet to be fully discovered. Recently, a number of evidences show that dysregulation of microRNAs (miRNAs) induces carcinogenesis. In this study, we found miR-222 was upregulated in arsenic-transformed human lung epithelial BEAS-2B cells (As-T cells). Anti-miR-222 inhibitor treatment decreased cell proliferation, migration, tube formation, and induced apoptosis. In addition, anti-miR-222 inhibitor expression decreased tumor growth in vivo. We also found that inhibition of miR-222 induced the expression of its direct targets ARID1A and phosphatase and tensin homolog deleted on chromosome 10 (PTEN), and activated apoptosis of As-T cells in part through ARID1A downregulation. These results indicate that miR-222 plays an important role in arsenic-induced tumor growth.
Oncogenic Roles and Mechanisms of Lncrna AGAP2-AS1 in Human Solid Tumors.

Zhengyi Bao,Qiuxian Zheng,Lanjuan Li

2021-01-01

American journal of translational research

Abstract:Cancer remains the second leading life-threatening disease worldwide. Increasing evidence indicates that long non-coding RNAs (lncRNAs) play an important role in multiple physiological and pathological processes, including gene amplification, mutation, rearrangement, and overexpression regulations. In this review, we comprehensively summarize the current knowledge of lncRNA AGAP2-AS1 from a cancer perspective. As a member of the lncRNA family, lncRNA AGAP2-AS1 is upregulated in solid tumor malignancies, functions as an oncogene, and plays a key role in tumorigenesis and tumor progression. AGAP2-AS1 expression is significantly increased in clinical cancer tissue samples, cell lines, and in vivo, and is closely related to an unfavorable prognosis in several cancers. Upregulated lncRNA AGAP2-AS1 binds with microRNAs (miRNAs) and promotes activation of downstream genes. This aberrant regulation induces carcinogenesis and tumorigenesis. Here we provide a comprehensive overview of AGAP2-AS1 in cancer progression that leads to an improved understanding of the effects of AGAP2-AS1 on early detection and therapeutic approaches. This information is essential for the future development of lncRNA AGAP2-AS1 as a potential therapy against these devastating cancers.
Induction of the Mesenchymal to Epithelial Transition by Demethylation- Activated Microrna-200C is Involved in the Anti-Migration/invasion Effects of Arsenic Trioxide on Human Breast Cancer Cells.

Lu Si,Fei Jiang,Yuan Li,Xianqing Ye,Juan Mu,Xingxing Wang,Shilong Ning,Chunyan Hu,Zhong Li

DOI: https://doi.org/10.1002/mc.22157

2014-01-01

Molecular Carcinogenesis

Abstract:Breast cancer is a major health problem worldwide. Current standard practices for treatment of breast cancer are less than satisfactory because of high rates of metastasis. Arsenic trioxide (As2O3), which induces demethylation of DNA and causes apoptosis, has been used as an anti‐tumor agent. Little is known, however, regarding its anti‐metastatic effects. The microRNA‐200c (miR‐200c), which is frequently lowly expressed in triple negative breast cancers (TNBCs), inhibits metastasis by inducing the mesenchymal to epithelial transition (MET). Here, we report that As2O3 attenuates the migratory and invasive capacities of breast cancer cells, MDA‐MB‐231 and BT‐549. Notably, As2O3 induces an MET in vitro and in vivo, as determined by the increased expression of the epithelial marker, E‐cadherin and decreased expressions of mesenchymal markers, N‐cadherin and vimentin. Moreover, As2O3 up‐regulates the expression of miR‐200c through demethylation. Over‐expression of miR‐200c enhances the expression of E‐cadherin and decreases the expressions of N‐cadherin and vimentin. Further, in MDA‐MB‐231 cells exposed to As2O3, knockdown of miR‐200c blocks the As2O3‐induced MET. Finally, in MDA‐MB‐231 and BT‐549 cells exposed to As2O3, knockdown of miR‐200c decreases the As2O3‐induced inhibition of the migratory and invasive capacities. By identifying a mechanism whereby As2O3 regulates miR‐200c and MET, the results establish the anti‐migration/invasion potential of arsenic trioxide. © 2014 Wiley Periodicals, Inc.
The Overexpression of Multidrug Resistance-Associated Proteins and Gankyrin Contribute to Arsenic Trioxide Resistance in Liver and Gastric Cancer Cells

Xi Chen,Mu Zhang,Lian-Xin Liu

DOI: https://doi.org/10.3892/or_00000408

2009-01-01

Oncology Reports

Abstract:Arsenic trioxide has been used as a therapeutic agent for acute promyelocytic leukemia and recently for some solid tumors. Although arsenic trioxide has been shown to significantly inhibit the growth of solid tumor cells in vitro, clinical trials indicate that arsenic trioxide alone is pool active against non-hematologic malignant diseases. To understand the mechanisms of arsenic resistance in solid tumor cells, we established two arsenic-resistant solid tumor cell lines, HepG2/AS and SGC7901/AS, isolated from human liver cancer cell line HepG2 and human gastric cancer cell line SGC7901, respectively, by a series of stepwise selections via treatment with increasing concentrations of arsenic trioxide. Three ABC transporter proteins, ABCB1, ABCC1 and ABCC2, were expressed increasingly and differently in two arsenic-resistant cell lines. Further, tumor suppressor p53 was overexpressed in two arsenic-resistant cell lines, but the levels of p53 mediators MDM2 and gankyrin, which regulate the ubiquitination of p53, increased simultaneously. In addition, an increase in the phosphorylation of Rb at Ser795 in the two cell lines might also result from the presence of MDM2 and gankyrin, which suggest that the inactivation of p53 and Rb contribute to drug resistance. These two arsenic-resistant solid tumor cell lines, HepG2/AS and SGC7901/AS, may be useful for studying the mechanism of arsenic resistance in solid tumors and may provide a way to overcome it.
[On the estimate of the number of genetic factors responsible for stature. 1. At age 17-21 years (author's transl)].

T. Furusho

1973-09-01

Abstract:
miRNAs and arsenic-induced carcinogenesis

Alexandra N Nail,Ana P Ferragut Cardoso,Lakyn K Montero,J Christopher States

DOI: https://doi.org/10.1016/bs.apha.2022.10.002

Abstract:Arsenic-induced carcinogenesis is a worldwide health problem. Identifying the molecular mechanisms responsible for the induction of arsenic-induced cancers is important for developing treatment strategies. MicroRNA (miRNA) dysregulation is known to affect development and progression of human cancer. Several studies have identified an association between altered miRNA expression in cancers from individuals chronically exposed to arsenic and in cell models for arsenic-induced carcinogenesis. This chapter provides a comprehensive review for miRNA dysregulation in arsenic-induced cancer.
Arsenic-Induced Carcinogenesis: The Impact of miRNA Dysregulation

Ana P Ferragut Cardoso,Laila Al-Eryani,J Christopher States

DOI: https://doi.org/10.1093/toxsci/kfy128

2018-10-01

Abstract:Arsenic is a toxic metalloid widely present in the earth's crust, and is a proven human carcinogen. Chronic arsenic exposure mainly through drinking water causes skin, lung, and urinary bladder cancers, and is associated with liver, prostate, and kidney cancers, cardiovascular and neurological disorders, and diabetes. Several modes of action have been suggested in arsenic carcinogenesis. However, the molecular etiology of arsenic-induced cancer remains unclear. Recent evidence clearly indicates that gene expression modifications induced by arsenic may involve epigenetic alterations, including miRNA dysregulation. Many miRNAs have been implicated in different human cancers as a consequence of losses and or gains of miRNA function that contribute to cancer development. Progress in identifying miRNA dysregulation induced by arsenic has been made using different approaches and models. The present review discusses the recent data regarding dysregulated expression of miRNA in arsenic-induced malignant transformation in vitro, gaps in current understanding and deficiencies in current models for arsenic-induced carcinogenesis, and future directions of research that would improve our knowledge regarding the mechanisms involved in arsenic-induced carcinogenesis.
How MicroRNAs Command the Battle against Cancer

Hong Helena Wu,Sarah Leng,Consolato Sergi,Roger Leng

DOI: https://doi.org/10.3390/ijms25115865

IF: 5.6

2024-05-29

International Journal of Molecular Sciences

Abstract:MicroRNAs (miRNAs) are small RNA molecules that regulate more than 30% of genes in humans. Recent studies have revealed that miRNAs play a crucial role in tumorigenesis. Large sets of miRNAs in human tumors are under-expressed compared to normal tissues. Furthermore, experiments have shown that interference with miRNA processing enhances tumorigenesis. Multiple studies have documented the causal role of miRNAs in cancer, and miRNA-based anticancer therapies are currently being developed. This review primarily focuses on two key points: (1) miRNAs and their role in human cancer and (2) the regulation of tumor suppressors by miRNAs. The review discusses (a) the regulation of the tumor suppressor p53 by miRNA, (b) the critical role of the miR-144/451 cluster in regulating the Itch-p63-Ago2 pathway, and (c) the regulation of PTEN by miRNAs. Future research and the perspectives of miRNA in cancer are also discussed. Understanding these pathways will open avenues for therapeutic interventions targeting miRNA regulation.

biochemistry & molecular biology,chemistry, multidisciplinary
Regulation of MicroRNA-497-Targeting AKT2 Influences Tumor Growth and Chemoresistance to Cisplatin in Lung Cancer

Lin Wang,Xiang-Bo Ji,Li-Hong Wang,Jian-Ge Qiu,Feng-Mei Zhou,Wen-Jing Liu,Di-di Wan,Marie Chai-mi Lin,Ling-Zhi Liu,Jian-Ying Zhang,Bing-Hua Jiang

DOI: https://doi.org/10.3389/fcell.2020.00840

IF: 5.5

2020-09-08

Frontiers in Cell and Developmental Biology

Abstract:Background: MicroRNA-497 (miR-497) has been implicated in several cancers. Increasing studies demonstrate the role of AKT2 in cancers as an oncogene which is closely associated with tumor aggressiveness by enhancing cancer cell survival, migration and invasion However, miR-497/AKT2 axis in non-small cell lung cancer (NSCLC) remains unclear.Methods: Quantitative real-time PCR (qRT-PCR) was used to quantify the expression of miR-497 and its target gene. The function of miR-497 in lung cancer was investigated through in vitro and in vivo assays (cell proliferation assay, cell migration assay, colony formation assay, flow cytometry assay, immunoblotting and tumorigenesis assay). Luciferase reporter assay was conducted to confirm the target gene of miR-497.Results: In this study, we found that miR-497 was significantly downregulated in tumor tissues and blood samples of lung cancer patients. To understand the potential mechanism of miR-497 in inhibiting tumor growth, we showed that miR-497 blocked the activation of AKT2 and regulated cell proliferation, cell migration, colony formation and increases chemosensitivity of H1299 cells to cisplatin by inhibiting AKT2. MiR-497 also inhibited tumor growth and suppressed expression of AKT2 at the protein and mRNA levels in mouse xenograft tumors.Conclusion: Taken together, our findings indicated that miR-497 suppresses the tumor growth by targeting AKT2, and the miR-497/AKT2 axis is a potential therapeutic target for NSCLC intervention.

cell biology,developmental biology
Effect of Maize Hybrid and Foliar Fungicides on Yield Under Low Foliar Disease Severity Conditions.

S. Mallowa,P. Esker,P. Paul,C. Bradley,V. Chapara,S. Conley,A. Robertson

DOI: https://doi.org/10.1094/PHYTO-08-14-0210-R

2015-07-31

Phytopathology

Abstract:Foliar fungicide use in the U.S. Corn Belt increased in the last decade; however, questions persist pertaining to its value and sustainability. Multistate field trials were established from 2010 to 2012 in Illinois, Iowa, Ohio, and Wisconsin to examine how hybrid and foliar fungicide influenced disease intensity and yield. The experimental design was in a split-split plot with main plots consisting of hybrids varying in resistance to gray leaf spot (caused by Cercospora zeae-maydis) and northern corn leaf blight (caused by Setosphaera turcica), subplots corresponding to four application timings of the fungicide pyraclostrobin, and sub-subplots represented by inoculations with either C. zeae-maydis, S. turcica, or both at two vegetative growth stages. Fungicide application (VT/R1) significantly reduced total disease severity relative to the control in five of eight site-years (P<0.05). Disease was reduced by approximately 30% at Wisconsin in 2011, 20% at Illinois in 2010, 29% at Iowa in 2010, and 32 and 30% at Ohio in 2010 and 2012, respectively. These disease severities ranged from 0.2 to 0.3% in Wisconsin in 2011 to 16.7 to 22.1% in Illinois in 2010. The untreated control had significantly lower yield (P<0.05) than the fungicide-treated in three site-years. Fungicide application increased the yield by approximately 6% at Ohio in 2010, 5% at Wisconsin in 2010 and 6% in 2011. Yield differences ranged from 8,403 to 8,890 kg/ha in Wisconsin 2011 to 11,362 to 11,919 kg/ha in Wisconsin 2010. Results suggest susceptibility to disease and prevailing environment are important drivers of observed differences. Yield increases as a result of the physiological benefits of plant health benefits under low disease were not consistent.
miRNA-based biomarkers, therapies, and resistance in Cancer

Boxue He,Zhenyu Zhao,Qidong Cai,Yuqian Zhang,Pengfei Zhang,Shuai Shi,Hui Xie,Xiong Peng,Wei Yin,Yongguang Tao,Xiang Wang

DOI: https://doi.org/10.7150/ijbs.47203

2020-01-01

International Journal of Biological Sciences

Abstract:MicroRNAs (miRNAs), small non-coding RNAs (ncRNAs) of about 22 nucleotides in size, play important roles in gene regulation, and their dysregulation is implicated in human diseases including cancer. A variety of miRNAs could take roles in the cancer progression, participate in the process of tumor immune, and function with miRNA sponges. During the last two decades, the connection between miRNAs and various cancers has been widely researched. Based on evidence about miRNA, numerous potential cancer biomarkers for the diagnosis and prognosis have been put forward, providing a new perspective on cancer screening. Besides, there are several miRNA-based therapies among different cancers being conducted, advanced treatments such as the combination of synergistic strategies and the use of complementary miRNAs provide significant clinical benefits to cancer patients potentially. Furthermore, it is demonstrated that many miRNAs are engaged in the resistance of cancer therapies with their complex underlying regulatory mechanisms, whose comprehensive cognition can help clinicians and improve patient prognosis. With the belief that studies about miRNAs in human cancer would have great clinical implications, we attempt to summarize the current situation and potential development prospects in this review.

biochemistry & molecular biology
A Report of Two Cases of Kala-Azar with Delirium as a Prominent Feature

K. Bhaskaran

1949-04-01

Abstract:or extreme rarity of mental symptoms like delirium, mental drowsiness, etc., in kala-azar. This is one of the few negative points of diagnostic significance in clinical medicine. Even in ' enteric type ' of the disease, though the case may simulate one of enteric fever very closely, the toxic drowsiness of the enteric patient is conspicuous by its absence. Even in what Manson-Bahr terms the 1 acute toxic ' type with very high mortality mental symptoms
Exploiting the therapeutic potential of microRNAs in human cancer

William CS Cho

DOI: https://doi.org/10.1517/14728222.2012.663354

IF: 6.797

2012-02-18

Expert Opinion on Therapeutic Targets

Abstract:Dysregulation of microRNAs (miRNAs) has been widely shown to be associated with the development and progression of cancer. Recent studies discovered a handful of miRNAs with great potential to act as therapeutic targets in various human cancers. Inhibition or overexpression of these oncomirs may regulate the expressions of their associated genes, which in turn represses the proliferation or metastasis of different cancers. Some miRNAs can reverse the phenotype of epithelial-mesenchymal transition, while others can be utilized to sensitize cells to DNA-damaging drugs. Most of their anticancer abilities have been validated in preclinical animal models. A merit of miRNA-based therapy is that it can target plenty of genes in different signaling pathways, but this also comes with the drawback of many unknown off-target effects. In addition, successful delivery is also a major obstacle to effective miRNA-based therapeutics. Nevertheless, new findings from recent studies and the rapid advances in systemic drug delivery systems provide an optimistic perspective on the evolution of the field.

pharmacology & pharmacy
Anti-liver cancer effect and the mechanism of arsenic sulfide in vitro and in vivo

Shudan Wang,Chao Zhang,Yumei Li,Ping Li,Dafang Zhang,Chaoying Li

DOI: https://doi.org/10.1007/s00280-018-3755-9

2018-12-12

Cancer Chemotherapy and Pharmacology

Abstract:PurposeThis study aimed at investigating the anti-tumor effect of arsenic sulfide (As2S2) against liver cancer both in vivo and in vitro and to elucidate its underlying mechanisms.MethodsCell viability of the human hepatocellular carcinoma cell lines SMMC-7721, BEL-7402, HepG2 were measured by CCK-8 assay. The effects of As2S2 on cell proliferation and apoptosis of SMMC-7721 cells were investigated using Calcein-AM and PI staining, Hoechst 33258 staining, crystal violet staining, and JC-1 staining. Cell cycle and Annexin V/PI assay were analyzed via flow cytometry. The expression of apoptosis-related proteins, phosphorylation of PI3K and AKT were detected by Western blotting. H22-bearing mice model was established to evaluate the anti-tumor effect of As2S2 in vivo. HE staining, PCNA was observed via immunohistochemistry, and TUNEL assay was used to assess the anti-proliferation and pro-apoptotic effects of As2S2.ResultsAs2S2 significantly inhibited the growth of human hepatoma cells SMMC-7721, BEL-7402 and HepG2. As2S2 inhibited cell proliferation effectively by inducing G0/G1 cell cycle arrest in SMMC-7721 cells. As2S2 could increase Bax/Bcl-2 ratio, decrease mitochondrial membrane potential, promote the release of cytochrome c, increase the levels of cleaved caspase-3 and PARP, indicating that As2S2 induced apoptosis in SMMC-7721 cells via mitochondrial-mediated apoptosis pathway. Further research showed that As2S2 inhibited the PI3K/AKT signaling pathway leading to apoptotic cell death. In addition, As2S2 significantly inhibited tumor growth in H22-bearing mice and induced apoptosis by deactivating PI3K/AKT pathway, which was consistent with the in vitro results.ConclusionThese findings suggested that As2S2 could induce apoptosis of liver cancer cells in vitro and in vivo, which was related to PI3K/AKT-mediated mitochondrial pathway and may provide a novel promising therapeutic agent for liver cancer treatment.

oncology,pharmacology & pharmacy
Metabolism, toxicity and anticancer activities of arsenic compounds

Islam Khairul,Qian Qian Wang,Yu Han Jiang,Chao Wang,Hua Naranmandura

DOI: https://doi.org/10.18632/oncotarget.14733

2017-01-18

Oncotarget

Abstract:A variety of studies indicated that inorganic arsenic and its methylated metabolites have paradoxical effects, namely, carcinogenic and anticancer effects. Epidemiological studies have shown that long term exposure to arsenic can increase the risk of cancers of lung, skin or bladder in man, which is probably associated with the arsenic metabolism. In fact, the enzymatic conversion of inorganic arsenic by Arsenic (+3 oxidation state) methyltransferase (AS3MT) to mono- and dimethylated arsenic species has long been considered as a major route for detoxification. However, several studies have also indicated that biomethylation of inorganic arsenic, particularly the production of trivalent methylated metabolites, is a process that activates arsenic as a toxin and a carcinogen. On the other hand, arsenic trioxide (As2O3) has recently been recognized as one of the most effective drugs for the treatment of APL. However, elaboration of the cytotoxic mechanisms of arsenic and its methylated metabolites in eradicating cancer is sorely lacking. To provide a deeper understanding of the toxicity and carcinogenicity along with them use of arsenic in chemotherapy, caution is required considering the poor understanding of its various mechanisms of exerting toxicity. Thereby, in this review, we have focused on arsenic metabolic pathway, the roles of the methylated arsenic metabolites in toxicity and in the therapeutic efficacy for the treatments of solid tumors, APL and/or non-APL malignancies.

VT begets VT--and other bad stuff--in patients treated with CRT-D.

Molecular Mechanisms and Clinical Applications of Mir-22 in Regulating Malignant Progression in Human Cancer (Review)

Mir-22 Has a Potent Anti-Tumour Role with Therapeutic Potential in Acute Myeloid Leukaemia

Depletion of Ars2 inhibits cell proliferation and leukemogenesis in acute myeloid leukemia by modulating the miR-6734-3p/p27 axis

MicroRNA-191, Regulated by HIF-2α, is Involved in EMT and Acquisition of a Stem Cell-Like Phenotype in Arsenite-Transformed Human Liver Epithelial Cells.

Microrna Expression Alteration after Arsenic Trioxide Treatment in HepG‐2 Cells

Role and Mechanism of Mir-222 in Arsenic-Transformed Cells for Inducing Tumor Growth

Oncogenic Roles and Mechanisms of Lncrna AGAP2-AS1 in Human Solid Tumors.

Induction of the Mesenchymal to Epithelial Transition by Demethylation- Activated Microrna-200C is Involved in the Anti-Migration/invasion Effects of Arsenic Trioxide on Human Breast Cancer Cells.

The Overexpression of Multidrug Resistance-Associated Proteins and Gankyrin Contribute to Arsenic Trioxide Resistance in Liver and Gastric Cancer Cells

[On the estimate of the number of genetic factors responsible for stature. 1. At age 17-21 years (author's transl)].

miRNAs and arsenic-induced carcinogenesis

Arsenic-Induced Carcinogenesis: The Impact of miRNA Dysregulation

How MicroRNAs Command the Battle against Cancer

Regulation of MicroRNA-497-Targeting AKT2 Influences Tumor Growth and Chemoresistance to Cisplatin in Lung Cancer

Effect of Maize Hybrid and Foliar Fungicides on Yield Under Low Foliar Disease Severity Conditions.

miRNA-based biomarkers, therapies, and resistance in Cancer

A Report of Two Cases of Kala-Azar with Delirium as a Prominent Feature

Exploiting the therapeutic potential of microRNAs in human cancer

Anti-liver cancer effect and the mechanism of arsenic sulfide in vitro and in vivo

Metabolism, toxicity and anticancer activities of arsenic compounds